Paper - WANFANG MED ONLINE

You Position: Home > Paper

Attention should be paid to the comprehensively standardized treatment of tracheobronchial tuberculosis

( views:0, downloads:0 )

Author:: No author available

Journal Title:: Chinese Journal of Tuberculosis and Respiratory Diseases

Issue:: 4

DOI:: 10.3760/cma.j.cn112147-20210113-00041

Key Word:: No keyword available

Abstract：气管支气管结核作为肺结核特殊临床类型，临床上极易被误治漏治。为进一步加强对本病全面合理治疗的认识，特强调重视气管支气管结核的综合规范治疗，尤其是介入治疗措施选择。

Reference

[1]郭燕,尹丹丹,胡付品,等.碳青霉烯类耐药革兰阴性菌对黏菌素和多黏菌素B的药敏试验方法学评价[J].2020,(5).
[2]许磊,季京淑,张慧川,等.铜绿假单胞菌多黏菌素异质性耐药及联合药敏研究[J].2015,(12).
[3]欧洲临床微生物和感染病学会药敏委员会华人抗菌药物敏感性试验委员会,中国医药教育协会感染疾病专业委员会,杨启文,等.多黏菌素药物敏感性检测及临床解读专家共识[J].2020,(5).
[4]钱鎏佳,陈代杰,林惠敏.多黏菌素异质性耐药鲍曼不动杆菌的研究[J].2017,(3).
[5]张思琴,卢鸿,曹建明,等.体外联合用药对黏菌素异质性耐药鲍曼不动杆菌的抗菌活性研究[J].2018,(8).
[6]Avedissian, Sean N.,Miglis, Cristina,Kubin, Christine J.,etc.Polymyxin B Pharmacokinetics in Adult Cystic Fibrosis Patients[J].2018,38(7).
[7]Landersdorfer, Cornelia B.,Wang, Jiping,Wirth, Veronika,etc.Pharmacokinetics/pharmacodynamics of systemically administered polymyxin B against Klebsiella pneumoniaein mouse thigh and lung infection models[J].2018,73(2).
[8]Andrea Kwa,Sofia K Kasiakou,Vincent H Tam,etc.Polymyxin B: similarities to and differences from colistin (polymyxin E)[J].2007,5(5).
[9]王影,李艳然,韩镌竹,等.多粘菌素耐药性的研究进展[J].2017,(1).
[10]Yilmaz,G.R.,Ba?tu?,A.T.,But,A.,etc.Clinical and microbiological efficacy and toxicity of colistin in patients infected with multidrug-resistant gram-negative pathogens[J].2013,19(1).
[11]Sandri,A.M.,Landersdorfer,C.B.,Jacob,J.,etc.Population pharmacokinetics of intravenous polymyxin B in critically Ill patients: Implications for selection of dosage regimens[J].2013,57(4).
[12]Moosavian, Mojtaba,Shoja, Saeed,Nashibi, Roohangiz,etc.Post Neurosurgical Meningitis due to Colistin Heteroresistant Acinetobacter baumannii.[J].2014,7(10).
[13]Boyle MJ,Kelly JA,Ferguson JK,etc.Cure of multiresistant Acinetobacter baumannii central nervous system infections with intraventricular or intrathecal colistin: case series and literature review.[J].2006,58(5).
[14]Miglis, Cristina,Rhodes, Nathaniel J.,Avedissian, Sean N.,etc.Population Pharmacokinetics of Polymyxin B in Acutely III Adult Patients[J].2018,62(3).
[15]Corcione,A.,Mattei,A.,Mocavero,P.,etc.Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: A multicenter, randomized clinical trial[J].2013,57(3).
[16]Png K,Wareham DW,Gordon NC.Potent synergy and sustained bactericidal activity of a vancomycin-colistin combination versus multidrug-resistant strains of Acinetobacter baumannii.[J].2010,54(12).
[17]Barin Juliana,Martins Andreza Francisco,Heineck Bianca Lucia,etc.Hetero- and adaptive resistance to polymyxin B in OXA-23-producing carbapenem-resistant Acinetobacter baumannii isolates[J].2013,12(1).
[18]第二届微生物学名词审定委员会.微生物学名词[M].2012.
[19]Ali Faisal Saleem,Muhammad Shafaat Shah,Abdul Sattar Shaikh,etc.Acinetobacter species meningitis in children: a case series from Karachi, Pakistan[J].2011,5(11).
[20]Rattanaumpawan P,Lorsutthitham J,Ungprasert P,etc.Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria.[J].2010,65(12).
[21]Yun Cai,Dong Chai,Rui Wang,etc.Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies[J].2012,67 (7 ).
[22]Mosca,A.,Spada,M.L.,Puntillo,F.,etc.High-dose, extended-interval colistin administration in critically ill patients: Is this the right dosing strategy? a preliminary study[J].2012,54(12).
[23]Aruna, Nigam,Archana, Kumari,Reena, Jain,etc.Colistin neurotoxicity: revisited.[J].2015,2015.
[24].Antimicrobials for the treatment of drug-resistant Acinetobacter baumannii pneumonia in critically ill patients: a systemic review and Bayesian network meta-analysis.[J].2017,21(1).
[25]Coulthard K,Bergen PJ,Turnidge JD,etc.Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model.[J].2008,61(3).
[26]Jacobs, M.,Gregoire, N.,Megarbane, B.,etc.Population Pharmacokinetics of Colistin Methanesulfonate and Colistin in Critically Ill Patients with Acute Renal Failure Requiring Intermittent Hemodialysis[J].2016,60(3).
[27]Miao, Zhao,Xiao-Jie, Wu,Ya-Xin, Fan,etc.Pharmacokinetics of colistin methanesulfonate (CMS) in healthy chinese subjects after single and multiple intravenous doses.[J].2018,(Spec ).
[28].Polymyxin Susceptibility Testing and Interpretive Breakpoints: Recommendations from the United States Committee on Antimicrobial Susceptibility Testing (USCAST)[J].2020,64(2).
[29]Ji Young Jang,Hye Youn Kwon,Eun Hee Choi,etc.Efficacy and toxicity of high-dose nebulized colistin for critically ill surgical patients with ventilator-associated pneumonia caused by multidrug-resistant Acinetobacter baumannii[J].2017,40.
[30]Karaiskos, Ilias,Friberg, Lena E.,Galani, Lambrini,etc.Challenge for higher colistin dosage in critically ill patients receiving continuous venovenous haemodiafiltration[J].2016,48(3).
[31]Karvanen M,Plachouras D,Friberg LE.Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria.[J].2009,53(8).
[32]Tunkel, Allan R.,Hasbun, Rodrigo,Bhimraj, Adarsh,etc.2017 Infectious Diseases Society of America's Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis[J].2017,64(6).
[33]Nation RL,Rayner CR,Li J,etc.Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii.[J].2006,50(9).
[34]Vourli, Sophia,Dafopoulou, Konstantina,Vrioni, Georgia,etc.Evaluation of two automated systems for colistin susceptibility testing of carbapenem-resistant Acinetobacter baumannii clinical isolates[J].2017,72(9).
[35]Cheah, Soon-Ee,Wang, Jiping,Van Thi Thu Nguyen,etc.New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection[J].2015,70(12).
[36]K. P. H. Mattos,M. L. Cintra,I. R. Gouvêa,etc.Skin hyperpigmentation following intravenous polymyxin B treatment associated with melanocyte activation and inflammatory process[J].2017,42(5).
[37]Levin AS,Muller PR,Pereira GH.Salvage treatment of pneumonia and initial treatment of tracheobronchitis caused by multidrug-resistant Gram-negative bacilli with inhaled polymyxin B.[J].2007,58(2).
[38]Jian, Li,Roger L, Nation,Robert W, Milne,etc.Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria.[J].2005,25(1).
[39]Babitch, T.,Shofty, B.,Rappaport, Z. H.,etc.Intrathecal or intraventricular therapy for post-neurosurgical Gram-negative meningitis: matched cohort study[J].2016,22(1).
[40].热病:桑福德抗微生物治疗指南(新译第48版)[M].2019.
[41]Rabanal, Francesc,Cajal, Yolanda.Recent advances and perspectives in the design and development of polymyxins[J].2017,34(7).
[42]Falagas, Matthew E.,Kasiakou, Sofia K..Colistin: The Revival of Polymyxins for the Management of Multidrug-Resistant Gram-Negative Bacterial Infections.[J].2005,40(9).
[43]Leuppi-Taegtmeyer, Anne B.,Decosterd, Laurent,Osthoff, Michael,etc.Multicenter Population Pharmacokinetic Study of Colistimethate Sodium and Colistin Dosed as in Normal Renal Function in Patients on Continuous Renal Replacement Therapy[J].2019,63(2).
[44].International Consensus Guidelines for the Optimal Use of the Polymyxins.[J].2019,39(1).
[45].Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia[J].2013,141(6).
[46]Carlos Hernan, Rodriguez,Alejandra, De Ambrosio,Milena, Bajuk,etc.In vitro antimicrobials activity against endemic Acinetobacter baumannii multiresistant clones.[J].2010,4.
[47]Kelesidis, Theodoros,Falagas, Matthew E..The safety of polymyxin antibiotics[J].2015,14(11).
[48]Amy L, Dzierba,Darryl, Abrams,Daniel, Brodie.Medicating patients during extracorporeal membrane oxygenation: the evidence is building.[J].2017,21(1).
[49]Mizuyachi,K.,Hara,K.,Wakamatsu,A.,etc.Safety and pharmacokinetic evaluation of intravenous colistin methanesulfonate sodium in Japanese healthy male subjects[J].2011,27(12).
[50]Eric, Wenzler,Kristen L, Bunnell,Larry H, Danziger.Clinical use of the polymyxins: the tale of the fox and the cat.[J].2018,(Spec ).
[51]Paul M,Bishara J,Levcovich A,etc.Effectiveness and safety of colistin: prospective comparative cohort study.[J].2010,65(5).
[52]Christine J, Kubin,Brian C, Nelson,Cristina, Miglis,etc.Population Pharmacokinetics of Intravenous Polymyxin B from Clinical Samples.[J].2018,(Spec ).
[53]Kalin, Gamze,Alp, Emine,Coskun, Ramazan,etc.Use of high-dose IV and aerosolized colistin for the treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia: do we really need this treatment?[J].2012,18(6).
[54]Raquel, Girardello,Ana Paula, Cury,Maria Renata Gomes, Franco,etc.Colistin susceptibility testing and Vitek-2?: is it really useless?[J].2018,(Spec ).
[55]Mohamed Farouk Ahmed, Abdelsalam,Maged Salah, Abdalla,Hanan Salah El-Din, El-Abhar.A prospective, comparative clinical study between high dose colistin monotherapy and colistin-meropenem combined therapy for treatment of hospital-acquired pneumonia and ventilator-associated pneumonia with multidrug-resistant bacterial Klebsiella pneumon[J].2018,(Spec ).
[56]Karaiskos, Ilias,Friberg, Lena E.,Pontikis, Konstantinos,etc.Colistin Population Pharmacokinetics after Application of a Loading Dose of 9 MU Colistin Methanesulfonate in Critically Ill Patients[J].2015,59(12).
[57]Thompson,P.E.,Jacob,J.,Chen,G.,etc.Pharmacokinetics of four different brands of colistimethate and formed colistin in rats[J].2013,68(10).
[58]Jongsung,Hahn,Seungwon,Yang,Kyoung Lok,Min,etc.Population pharmacokinetics of intravenous sufentanil in critically ill patients supported with extracorporeal membrane oxygenation therapy.[J].2019,23(1).
[59]Yapa,S.W.S.,Li,J.,Patel,K.,etc.Pulmonary and systemic pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic fibrosis patients: Targeting advantage of inhalational administration[J].2014,58(5).
[60]Jayol, Aurelie,Nordmann, Patrice,Poirel, Laurent.Polymyxins: Antibacterial Activity, Susceptibility Testing, and Resistance Mechanisms Encoded by Plasmids or Chromosomes[J].2017,30(2).
[61]Hahn J.,Choi J. H.,Chang M. J..Pharmacokinetic changes of antibiotic, antiviral, antituberculosis and antifungal agents during extracorporeal membrane oxygenation in critically ill adult patients[J].2017,42(6).
[62]Manchandani, Pooja,Thamlikitkul, Visanu,Dubrovskaya, Yanina,etc.Population Pharmacokinetics of Polymyxin B[J].2018,104(3).
[63]Berglund, Bjorn,Ngoc Thi Bich Hoang,Tarnberg, Maria,etc.Colistin- and carbapenem-resistant Klebsiella pneumoniae carrying mcr-1 and bla(OXA-48) isolated at a paediatric hospital in Vietnam[J].2018,73(4).
[64]Karvanen,M.,Plachouras,D.,Friberg,L.E.,etc.Colistin methanesulfonate and colistin pharmacokinetics in critically ill patients receiving continuous venovenous hemodiafiltration[J].2013,57(1).
[65]Hawley JS,Murray CK,Jorgensen JH.Colistin heteroresistance in acinetobacter and its association with previous colistin therapy.[J].2008,52(1).
[66]Lutz L,Nation RL,Goldani LZ,etc.Pharmacokinetics of intravenous polymyxin B in critically ill patients.[J].2008,47(10).
[67]Zavascki, Alexandre P.,Schuster, Luiza F.,Duquia, Rodrigo P..Histopathological findings of pigmented lesion and recovery of natural skin colour in a patient with polymyxin B-associated diffuse hyperpigmentation[J].2016,48(5).
[68]Tony Velkov,Chongshan Dai,Giuseppe D. Ciccotosto,etc.Polymyxins for CNS infections: Pharmacology and neurotoxicity[J].2018,181.
[69]Leangapichart, Thongpan,Gautret, Philippe,Brouqui, Philippe,etc.Acquisition of mcr-1 Plasmid-Mediated Colistin Resistance in Escherichia coli and Klebsiella pneumoniae during Hajj 2013 and 2014[J].2016,60(11).
[70]Imlay, J.A..The molecular mechanisms and physiological consequences of oxidative stress: Lessons from a model bacterium[J].2013,11(7).
[71]Manchandani, Pooja,Zhou, Jian,Babic, Jessica T.,etc.Role of Renal Drug Exposure in Polymyxin B-Induced Nephrotoxicity[J].2017,61(4).
[72]Nation, Roger L.,Li, Jian,Cars, Otto,etc.Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus[J].2015,15(2).
[73]Horcajada, Juan P.,Sorli, Luisa,Luque, Sonia,etc.Validation of a colistin plasma concentration breakpoint as a predictor of nephrotoxicity in patients treated with colistin methanesulfonate[J].2016,48(6).
[74]Nation, Roger L.,Garonzik, Samira M.,Thamlikitkul, Visanu,etc.Dosing Guidance for Intravenous Colistin in Critically Ill Patients[J].2017,64(5).
[75]W Couet,N Grégoire,P Gobin,etc.Pharmacokinetics of Colistin and Colistimethate Sodium After a Single 80‐mg Intravenous Dose of CMS in Young Healthy Volunteers[J].2011,89(6).
[76]Lin G,Pankuch GA,Seifert H,etc.Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.[J].2008,52(1).
[77]Sorlí Luisa,Luque Sonia,Grau Santiago,etc.Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study[J].2013,13(1).
[78]Sirijatuphat,R.,Thamlikitkul,V..Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections[J].2014,58(9).
[79]Pan Sijun,Huang Xiaofang,Wang Yesong,etc.Efficacy of intravenous plus intrathecal/intracerebral ventricle injection of polymyxin B for post-neurosurgical intracranial infections due to MDR/XDR Acinectobacter baumannii: a retrospective cohort study[J].2018,7(1).
[80]El-Halfawy, Omar M.,Valvano, Miguel A..Antimicrobial Heteroresistance: an Emerging Field in Need of Clarity[J].2015,28(1).
[81]Falagas,M.E.,Lourida,P.,Poulikakos,P.,etc.Antibiotic treatment of infections due to carbapenem-resistant enterobacteriaceae: Systematic evaluation of the available evidence[J].2014,58(2).
[82]Michael A. Kohanski,Daniel J. Dwyer,Boris Hayete,etc.A Common Mechanism of Cellular Death Induced by Bactericidal Antibiotics[J].2007,130(5).
[83]Kalil, Andre C.,Metersky, Mark L.,Klompas, Michael,etc.Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society[J].2016,63(5).
[84]Konstantinos Z. Vardakas,Georgios L. Voulgaris,George Samonis,etc.Inhaled colistin monotherapy for respiratory tract infections in adults without cystic fibrosis: a systematic review and meta-analysis[J].2018,51(1).
[85]Daniel J Dwyer,Michael A Kohanski,Boris Hayete,etc.Gyrase inhibitors induce an oxidative damage cellular death pathway in Escherichia coli[J].2007,3(1).
[86]Garonzik SM,Li J,Thamlikitkul V,etc.Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients.[J].2011,55(7).
[87]Strunk,A.-K.,Schmidt,J.J.,Baroke,E.,etc.Single- and multiple-dose pharmacokinetics and total removal of colistin in a patient with acute kidney injury undergoing extended daily dialysis[J].2014,69(7).
[88]Nation RL,Rayner CR,Turnidge JD,etc.Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections.[J].2006,6(9).
[89]Forrest, Alan,Garonzik, Samira M.,Thamlikitkul, Visanu,etc.Pharmacokinetic/Toxicodynamic Analysis of Colistin-Associated Acute Kidney Injury in Critically Ill Patients[J].2017,61(11).
[90]Valachis, Antonis,Samonis, George,Kofteridi, Diamantis R..The Role of Aerosolized Colistin in the Treatment of Ventilator-Associated Pneumonia: A Systematic Review and Metaanalysis[J].2015,43(3).
[91]AnuchaApisarnthanarak,KiratiKengkla,KhachenKongpakwattana,etc.Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections: a systematic review and network meta-analysis[J].2018,73(1).